Eye imaging study for early geographic atrophy
Part of Eyes & vision clinical trials.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You must have a doctor's diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD).
- The area of GA in your eye must be between 1.25 and 23 square millimeters, which your doctor can measure.
- You must be able to tolerate eye imaging tests.
- You cannot have wet (neovascular) AMD or any other retinal disease that could confuse the results.
- You have not had injections into the eye for geographic atrophy (such as Syfovre).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study looks closely at how age-related macular degeneration (AMD) develops and changes over time by taking detailed eye measurements. It may help researchers better understand disease progression, especially for people who already have AMD.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.